Online citations, reference lists, and bibliographies.
← Back to Search

Tolerability And Absorption Enhancement Of Intranasally Administered Octreotide By Sodium Taurodihydrofusidate In Healthy Subjects

T. Kissel, J. Drewe, S. Bantle, A. Rummelt, C. Beglinger
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Nasal sprays containing different concentrations of the somatostatin analogue octreotide and sodium tauro-24,25-dihydrofusidate (STDHF) as an absorption promoter were evaluated in two consecutive pharmacokinetic studies in healthy volunteers to characterize their bioavailability and local tolerability. The concentrations of STDHF were selected on the basis of a phase diagram generated by a dynamic laser light-scattering technique to ensure that the mixture was above the critical micellar concentrations. Compared to a 50-µg subcutaneous injection, the nasal spray formulation without STDHF had a mean relative bioavailability of 17.9%. For nasal formulations containing 3 and 1.65% (w/v) of STDHF, the bioavailability increased to 29.0 and 25.7%, respectively. The enhancement of nasal absorption was dependent on the STDHF concentrations as shown by decreasing the amounts to 1.2 and 0.8% (w/v) for tolerability reasons; the bioavailability was reduced to 15.3 and 20.5% in these cases, respectively. The local tolerability of all STDHF-containing sprays was poor, leading to stinging sensations and lacrimation. The poor local tolerability of the octreotide nasal spray containing different concentrations of STDHF required for effective nasal absorption enhancement appears to be impractical for further clinical development. These findings clearly stress the necessity to investigate tolerability and safety issues of new drug delivery systems in early developmental phases.
This paper references
[Transnasal administration of drugs. 2. Models for studying nasal absorption in animals and parameters susceptible to influence].
P. Wüthrich (1990)
10.1002/JPS.2600760502
Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.
J. Longenecker (1987)
10.1007/BF00560355
Pharmacokinetic criteria for the evaluation of retard formulations
J. Meier (2004)
10.1080/00031305.1981.10479327
Rank Transformations as a Bridge between Parametric and Nonparametric Statistics
W. Conover (1981)
Disposition of sandostatin, a new synthetic somatostatin analogue, in rats.
M. Lemaire (1989)
Octreotide, a new somatostatin analogue.
M. Katz (1989)
10.1023/A:1015904404442
Absorption Enhancement of Intranasally Administered Insulin by Sodium Taurodihydrofusidate (STDHF) in Rabbits and Rats
M. J. Deurloo (2004)
10.3109/00365528609034624
Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings.
P. Funch-Jensen (1986)
10.1023/A:1015885204249
The Effect of Sodium Tauro-24,25-Dihydrofusidate on the Nasal Absorption of Human Growth Hormone in Three Animal Models
Patricia A. Baldwin (2004)
10.2165/00003495-198938050-00002
Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
P. E. Battershill (1989)
10.1023/A:1015872617511
Effects of Absorption Enhancers on Human Nasal Tissue Ciliary Movement in Vitro
W. Hermens (2004)
10.1002/JPS.2600761206
Effect of bile salts on nasal permeability in vitro.
S. Hersey (1987)
10.1023/A:1015856430657
The Effects of Permeation Enhancers on the Surface Morphology of the Rat Nasal Mucosa: A Scanning Electron Microscopy Study
R. D. Ennis (2004)
Role of surface-active agents in drug absorption.
M. Gibaldi (1970)
10.2165/00003088-198917050-00001
Intranasal Drug Delivery
A. Pontiroli (1989)
10.1016/0163-7258(89)90113-7
Somatostatin and its analogues in the therapy of gastrointestinal disease.
D. Wynick (1989)
10.1073/PNAS.82.21.7419
Nasal absorption of insulin: enhancement by hydrophobic bile salts.
G. Gordon (1985)
10.3109/00365528609087433
Pharmacokinetics of SMS 201-995 in healthy subjects.
K. Kutz (1986)
10.1136/gut.30.9.1165
Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases.
L. O'Donnell (1989)



This paper is referenced by
10.22377/AJP.V2I4.203
Bioavailability of intranasal drug delivery system
S. B. Bhise (2008)
10.1007/BF00757627
In vitro tolerability of human nasal mucosa: histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin®
A. Fraissinette (2004)
10.1007/BF02976701
Enhancedex vivo buccal transport of propranolol: Evaluation of phospholipids as permeation enhancers
J. Lee (2003)
Factores que intervienen en el diseño de sistemas de liberación nasal de péptidos y proteínas
A. Muñoz-Cernada (2013)
10.1016/J.IJPHARM.2007.03.025
Intranasal delivery: physicochemical and therapeutic aspects.
H. Costantino (2007)
10.4333/KPS.2005.35.5.369
Buccal Delivery of [D-Ala 2 , D-Leu 5 ]Enkephalin Incorporated in Mucoadhesive Poly(acrylic acid) Hydrogels
J. Lee (2005)
10.1023/A:1016207809199
Effects of Absorption Enhancers on Rat Nasal Epithelium in Vivo: Release of Marker Compounds in the Nasal Cavity
E. Marttin (2004)
10.1097/00045391-200109000-00010
Inhalation therapy: new delivery systems.
V. Ranade (2001)
10.1016/0168-3659(96)01357-0
The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects
F. W. H. M. Merkus (1996)
INTRANASAL DRUG DELIVERY SYSTEM : A REVIEW
Pratikkumar A. Mistri (2012)
10.1016/S0169-409X(97)00059-8
Nasal mucociliary clearance as a factor in nasal drug delivery.
Merkus (1998)
10.1016/S0169-409X(97)00064-1
Optimization of systemic nasal drug delivery with pharmaceutical excipients.
Roméo (1998)
10.1023/A:1016210231121
Development of a Human Nasal Epithelial Cell Culture Model and Its Suitability for Transport and Metabolism Studies Under in Vitro Conditions
U. Werner (2004)
10.1023/B:PHAR.0000026823.82950.ff
Nasal route and drug delivery systems
S. Türker (2004)
10.1023/A:1018903407592
The Physicochemical Properties, Plasma Enzymatic Hydrolysis, and Nasal Absorption of Acyclovir and Its 2′-Ester Prodrugs
Z. Shao (2004)
10.1007/978-1-4020-6289-6_6
Alternative Applications for Drug Delivery: Nasal and Pulmonary Routes
A. Ozer (2007)
10.1248/CPB.56.1596
Design and evaluation of bioadhesive in-situ nasal gel of ketorolac tromethamine.
Sankar Chelladurai (2008)
Factors involved in the design of nasal delivery systems for peptides and proteins
A. Muñoz-Cernada (2013)
10.1016/S0169-409X(97)00063-X
Effects of physicochemical properties and other factors on systemic nasal drug delivery.
Roméo (1998)
RECENT TECHNIQUES IN NASAL DRUG DELIVERY: A REVIEW
Parmar Harshad (2010)
10.3109/1061186X.2010.492520
Polymer based solutions of bupranolol hydrochloride for intranasal systemic delivery
B. Mishra (2011)
10.1016/S0928-0987(99)00093-7
Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine.
S. Michael (2000)
10.3390/molecules14093754
Nasal Delivery of High Molecular Weight Drugs
Y. Ozsoy (2009)
10.1007/978-1-4020-6289-6
Nanomaterials and nanosystems for biomedical applications
M. R. Mozafari (2007)
Semantic Scholar Logo Some data provided by SemanticScholar